Prelude Capital Management’s Gilead Sciences GILD Stock Holding History

Prelude Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-16,300	Closed	-$1.06M	–	1634
2019 Q4	$1.06M	Buy	+16,300	New	+$1.06M	0.04%	370
2019 Q3	–	Sell	-40,000	Closed	-$2.7M	–	1825
2019 Q2	$2.7M	Sell	40,000 -10,000	-20%	-$658K	0.13%	128
2019 Q1	$3.25M	Buy	50,000 +10,000	+25%	+$665K	0.18%	99
2018 Q4	$2.5M	Buy	+40,000	New	+$2.8M	0.17%	131
2018 Q3	–	Sell	-35,000	Closed	-$2.48M	–	1833
2018 Q2	$2.48M	Buy	+35,000	New	+$2.47M	0.16%	115

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Prelude Capital Management's GILD Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Gilead Sciences (GILD) in Q1 2026: 1,783 shares worth $248K. The stake represents 0.02% of the portfolio and ranks #801 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in GILD as recently as Q2 2025.

Prelude Capital Management first reported a position in GILD in Q2 2013 and has held it in 38 quarters since. The position peaked at $3.91M in Q4 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Prelude Capital Management held 1,783 shares of Gilead Sciences worth $248K as of Q1 2026.
Gilead Sciences was a new Prelude Capital Management position in Q1 2026.
Gilead Sciences made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #801 holding.
Prelude Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 38 quarters since.
Prelude Capital Management's Gilead Sciences position peaked at $3.91M in Q4 2015.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.